PTC Therapeutics Inc. (PTCT) Wells Fargo 20th Annual Healthcare Conference 2025 Transcript

Tiago Fauth
Fairness Analyst

All proper. Thanks, everybody, for becoming a member of us. I am Tiago Fauth. I am a biotech analyst right here at Wells Fargo. We’ve PTC Therapeutics becoming a member of us at our well being care convention this 12 months. Thanks a lot for spending the time.

We’ve Matt and Pierre for a hearth chat. I often like to present you guys a while only for fast intros total setup. Once more, PTC has been modified considerably over the past 18 months, 2 years. So sure, should you can provide just like the temporary intro after which once more, an in depth dialogue on Sephience and a few features of the enterprise.

Matthew Klein
CEO & Director

Sure, completely. Thanks, Tiago. It is nice to be right here. And as you stated, we’re actually at a time limit at this time the place plenty of the work we have put in over the previous 1.5 years to 2 years to shed plenty of legacy challenges and place ourselves for future success has come to fruition. We not too long ago had our world approvals of Sephience start, together with each the U.S. and Europe. And as we talked about, we see that as a big industrial alternative for the corporate that may take us to money move breakeven and past within the close to future.

We closed the second quarter with over $1.9 billion in money. So we come to this time limit the place we will transfer in the direction of money move breakeven with enough capital within the financial institution, not solely to get us there, however execute on all of our industrial and R&D priorities as properly